2026-05-28 08:30
Biovica, specializing in blood-based cancer monitoring, today announced new data published in the European Journal of Cancer showing that DiviTumTKa can capture early, treatment-specific biological response in patients with endocrine-resistant HR+/HER2&minus...
2026-05-26 08:45
Biovica, active in blood-based cancer monitoring, today announced an expansion of an existing Pharma Services work order from a clinical-stage biopharmaceutical company developing a next-generation CDK inhibitor for solid tumors. The expanded work order...
2026-05-05 21:30
Biovica International AB (“Biovica”) today announces that the company’s Chief Financial Officer, Anders Morén, has resigned on his own initiative to pursue independent business activities. Anders Morén will remain in his...
2026-04-30 10:00
Biovica today announces that three posters including TKa measurements will be presented at ESMO Breast in Berlin on 6–8 May 2026. The presentations highlight how TKa can be used to monitor treatment response, disease progression and biological treatment...
2026-04-16 08:00
Biovica today announces that Theis Kipling will assume the role as Chief Executive Officer on May 1, 2026, earlier than previously communicated. In connection with this transition, Anders Rylander will step down as CEO and remain a member of the Board...
2026-04-07 08:30
The Biovica board has appointed Theis Kipling as the new Chief Executive Officer. He will assume the position no later than September 2026. Theis Kipling brings extensive international experience from leading global commercial organizations in the life...
2026-03-18 08:05
Biovica, a leader in blood-based biomarkers for cancer treatment monitoring, today announces two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The studies expand the evidence for circulating thymidine kinase...
2026-03-18 08:00
46% growth with strong momentum in the USA and for Pharma Services Q3 (Nov 2025–Jan 2026) (comparison figures are for the same period 2024/2025) Q1–Q3 (May 2025–Jan2026) (comparison figures are for the same period 2024/2025) Significant...
2026-03-09 17:00
The Nomination Committee prior to the 2026 Annual General Meeting will consist of four members, who shall represent the three shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December...
2026-03-05 15:30
The Board of Directors of Biovica International AB today announces that Chief Executive Officer Anders Rylander has informed the Board of his intention to step down as CEO during 2026, as part of a structured succession process. Anders Rylander will remain...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects